Annotated Medicine and Device Lists
| List | Section | Observation |
|---|---|---|
| WHO Model List of Essential Medicines (2021) | 6.4.4.1.1 Nucleoside/Nucleotide reverse transcriptase inhibitors | No observations |
| WHO Model List of Essential Medicines (2021) | 6.4.2.1. Nucleoside/Nucleotide reverse transcriptase inhibitors |
Others observations: (tenofovir disoproxil fumarate – equivalent to 245 mg tenofovir disoproxil). |
| PAHO Strategic Fund Medicine List | 2.6.1. Antiretrovirals | No observations |
| Trinidad and Tobago. Pharmaceutical Ven Listing 2019. Ministry of Health. | Anti-Retroviral Treatment Programme | No observations |
| Cuba. Cuadro Básico de Medicamentos 2018. Ministerio de Salud Pública. | CUADRO BÁSICO DE MEDICAMENTOS 2018. Ministerio de Salud Pública. |
Others observations: FCO X 30 TAB |
| Costa Rica. Caja Costarricense de Seguro Social. 2019 | 04. Antifungicos y Antivirales | No observations |
| Brasil. Relação Nacional de Medicamentos Essenciais. 2020 | J. ANTI-INFECCIOSOS PARA USO SISTEMICO | No observations |
| El Salvador - 2019 | ANTIVIRALES DE USO SISTÉMICO | No observations |
| Haiti. National List of Essential Medicines | 06.04.02.01 Nucleoside reverse transcriptase inhibitors | No observations |
| Haiti. National List of Essential Medicines | 06.04.04.01.01 Nucleoside/nucleotide reverse transcriptase inhibitors | No observations |
| List | Section | Observation |
|---|---|---|
| Mexico. Cuadro Basico de Medicamentos - 2017 | 06. ENFERMEDADES INFECCIOSAS Y PARASITARIAS | No observations |